By the Top Tier Newswire AI Desk · November 17, 2026 at 9:45 AM ET · reviewed against 21 wire stories
CG ONCOLOGY INC (CGON) is down -8.16% in the latest session. Our newswire has captured 21 stories on CGON across 9 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
CG Oncology (CGON) shares fell 8.16% to $77.86, driven by a mix of positive trial data and a new downgrade from RBC Capital. The stock had previously surged 30.8% over the last eight sessions, reaching a 52-week high before the current pullback.
What Happened
The primary catalyst for the session was the release of positive topline results from the Phase 3 PIVOT-006 trial. Following the data, several major banks adjusted their valuations. Truist raised its price target to $100 from $85, while JPMorgan lifted its target to $113 from $96. Wedbush and HC Wainwright & Co. also raised their targets to $91 and $115, respectively. Despite these upgrades, RBC Capital downgraded the stock to Sector Perform from Outperform. The company also reported third-quarter 2026 financial results, noting revenue growth of 183.6% on a trailing twelve-month basis.
What The Data Shows
The stock opened at $83.21, a 1.9% gap down from the prior close of $84.78. It traded as low as $77.11 at 9:45 AM ET before stabilizing near $77.68. Volume stood at 0.2 million shares, which is 0.2 times the three-month daily average. The company has a market capitalization of $6.6 billion and remains unprofitable with a trailing twelve-month EPS of -$2.78. Its beta is 0.35, and the 52-week range spans $37.01 to $93.95. Recent SEC filings show two sales by director Leonard E. Post totaling $135,000, with no buys in the last 90 days.
What To Watch
Analysts continue to debate the long-term valuation following the trial data. Investors should monitor the breadth of coverage, as 21 stories from nine sources were published in the last 36 hours. The upcoming earnings date is not specified in the current data set.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
CGON · Nov 17 session (5-min) · -6.82% vs prior close · updated 8:46 PM ETAI sentiment, last 36h · averaged over 21 stories · 63/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
3d agoGuruFocusBULLISH 63Analyst
CGON Maintained by Wedbush -- Price Target Raised to $91.00
3d agoThe FlyBULLISH 64Analyst
CG Oncology price target raised to $100 from $85 at Truist
3d agoGuruFocusBULLISH 63Analyst
CGON Maintained by HC Wainwright & Co. -- Price Target Raised to $115
3d agoInvesting.com Analyst RatingsBULLISH 64Analyst
Truist raises CG Oncology stock price target on trial results
Truist raises CG Oncology stock price target on trial results
3d agoThe FlyBULLISH 64Analyst
CG Oncology price target raised to $91 from $84 at Wedbush
3d agoInvesting.com Analyst RatingsBULLISH 64Analyst
JPMorgan raises CG Oncology stock price target on trial data
JPMorgan raises CG Oncology stock price target on trial data
3d agoThe FlyBULLISH 64Analyst
CG Oncology price target raised to $113 from $96 at JPMorgan
3d agoThe FlyBEARISH 34Analyst
CG Oncology downgraded to Sector Perform from Outperform at RBC Capital
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →